Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ranbaxy, Orchid Deal Seen Close To All-India Merger

This article was originally published in PharmAsia News

Executive Summary

India's Ranbaxy Group is considered close to a public offer for another Indian firm, Orchid Chemicals & Pharmaceuticals. The offer would be made through Solrex Pharmaceuticals, which is linked to Ranbaxy and which has increased its shares in Orchid to 14.7 percent. In India, a 15 per cent ownership is considered an offer to public shareholders and an intension to have a voice in the running of a company such as Orchid. Ranbaxy is seen as a potential beneficiary of Orchid's portfolio of antibiotics. Neither firm would comment. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts